Medifast Inc (NYSE:MED - Get Free Report) Director Parsa Kiai acquired 8,886 shares of the firm's stock in a transaction dated Wednesday, November 18th. The shares were acquired at an average price of $12.16 per share, for a total transaction of $108,053.76. Following the acquisition, the director directly owned 721,521 shares of the company's stock, valued at approximately $8,773,695.36. The trade was a 1.25% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Parsa Kiai also recently made the following trade(s):
- On Thursday, November 19th, Parsa Kiai acquired 85,150 shares of Medifast stock. The stock was bought at an average cost of $12.05 per share, with a total value of $1,026,057.50.
- On Wednesday, November 4th, Parsa Kiai bought 661 shares of Medifast stock. The stock was bought at an average price of $13.03 per share, with a total value of $8,612.83.
- On Wednesday, October 28th, Parsa Kiai bought 5,557 shares of Medifast stock. The stock was purchased at an average price of $12.24 per share, for a total transaction of $68,017.68.
- On Wednesday, August 26th, Parsa Kiai bought 43,150 shares of Medifast stock. The shares were acquired at an average price of $12.26 per share, for a total transaction of $529,019.00.
- On Monday, August 24th, Parsa Kiai purchased 4,329 shares of Medifast stock. The shares were acquired at an average price of $12.00 per share, with a total value of $51,948.00.
Medifast Stock Down 1.9%
MED traded down $0.23 during midday trading on Friday, reaching $11.75. 107,868 shares of the company's stock were exchanged, compared to its average volume of 200,250. The business has a 50-day simple moving average of $12.15 and a two-hundred day simple moving average of $11.41. The firm has a market capitalization of $131.33 million, a price-to-earnings ratio of -3.18 and a beta of 0.65. Medifast Inc has a one year low of $9.22 and a one year high of $13.63.
Medifast (NYSE:MED - Get Free Report) last released its quarterly earnings data on Monday, October 26th. The specialty retailer reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.16. Medifast had a negative return on equity of 6.90% and a negative net margin of 13.64%. The company had revenue of $72.05 million for the quarter, compared to analyst estimates of $71.30 million. As a group, research analysts anticipate that Medifast Inc will post -0.52 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of MED. State of Wyoming grew its stake in shares of Medifast by 19.8% in the first quarter. State of Wyoming now owns 6,646 shares of the specialty retailer's stock worth $68,000 after purchasing an additional 1,097 shares during the last quarter. Ancora Advisors LLC bought a new position in Medifast during the 2nd quarter worth $75,000. Advisors Asset Management Inc. acquired a new position in Medifast during the 3rd quarter worth about $106,000. Ieq Capital LLC acquired a new position in Medifast during the 2nd quarter worth about $114,000. Finally, Squarepoint Ops LLC acquired a new position in Medifast during the 2nd quarter worth about $214,000. Institutional investors and hedge funds own 95.51% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts have weighed in on MED shares. Weiss Ratings cut shares of Medifast from a "sell (d)" rating to a "sell (d-)" rating in a report on Wednesday, October 28th. Zacks Research cut Medifast from a "strong-buy" rating to a "hold" rating in a report on Wednesday, November 11th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Reduce" and a consensus target price of $12.00.
Get Our Latest Stock Analysis on MED
About Medifast
(
Get Free Report)
Medifast, Inc. is a health and wellness company focused on weight management and healthy living. Its products and programs are marketed primarily under the OPTAVIA brand. OPTAVIA offers structured plans that combine portion-controlled meal replacements and other nutrition products with guidance from independent coaches. The company's approach emphasizes nutrition, behavior changes and ongoing support. Founded in 1980, Medifast serves customers primarily in the United States. Its business centers on selling products and connecting customers with coaches who provide support as they follow the company's programs.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medifast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medifast wasn't on the list.
While Medifast currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.